CJC-1295: Mechanistic Overview
internal_protocolpreclinical · status: needs_provider_reviewDetails
Author: Axiom Knowledge Base
Citation: Internal reference summary compiled for the Axiom knowledge base (2026).
File: signed link
Summary (generated — provider review required)
CJC-1295 is a long-acting GHRH analog that increases GH/IGF-1 secretion. Mechanism: sustained stimulation of pituitary GH release; often discussed alongside ghrelin-receptor agonists. Relevance: recovery and body-composition contexts.
The original source document remains the source of truth. Generated summaries are not authoritative.
Linked assets (4) · phenotypes (0)
evidence_reference, mechanism, safety_reference, dosing_reference
Findings (4) · awaiting review (2)
outcome · pending
CJC-1295 is a long-acting GHRH analog that increases GH/IGF-1 secretion.
mechanism · pending
Mechanism: sustained stimulation of pituitary GH release; often discussed alongside ghrelin-receptor agonists.
safety · pending
Safety: human evidence limited; not an approved drug in many regions; glucose/IGF-1 monitoring considerations.
dosing · pending
Background for provider review only — not a treatment recommendation or dosing guidance.
Processing
Processed into 1 searchable section.